跳转至内容
Merck
CN

P-055

Supelco

普萘洛尔 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H21NO2·HCl
CAS号:
分子量:
295.80
EC 号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

Cl.CC(C)NCC(O)COc1cccc2ccccc12

InChI

1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H

InChI key

ZMRUPTIKESYGQW-UHFFFAOYSA-N

基因信息

一般描述

一种经认证的参比溶液,适用于临床和诊断测试、尿液药物测试、法医分析或临床毒理学的LC/MS或GC/MS测试方法的校准器和控制的起始材料。普萘洛尔是一种交感神经非选择性受体阻滞剂,用于治疗高血压、焦虑和恐慌等多种疾病。该药物以Inderal®、Avlocardyl、Deralin和Dociton等许多商品名出售。

应用

<ul>
<li><strong>用于婴儿血管瘤的盐酸普萘洛尔溶液:</strong>研究人员已经开发出用于治疗婴儿血管瘤的盐酸普萘洛尔脂质体制剂,研究为儿科皮肤病学领域提供了一种针对性的治疗方法(Nifli et al., 2024)。</li>
<li><strong>盐酸普萘洛尔:</strong>对于溶剂沉积(solvent-deposited)的盐酸普萘洛尔在不同皮肤层经皮吸收的研究提供了对其性质的见解,例如它可以用作剂量和电离状态的应变量,并可作为校准标准品 (Tonnis et al., 2024)。</li>
</ul>

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Inderal is a registered trademark of Cranford Pharmaceuticals, LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Retrospective review of adverse effects from propranolol in infants.
Eun-Kyung M Kwon et al.
JAMA dermatology, 149(4), 484-485 (2013-05-30)
[Propranolol first choice in infantile hemangiomas. Large randomized trials are needed to determine the dosage and duration of treatment].
Carl-Fredrik Wahlgren
Lakartidningen, 110(19-20), 938-939 (2013-06-12)
Bojko Bjelakovic et al.
Drug design, development and therapy, 7, 127-129 (2013-03-08)
We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant
Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study.
Imad R Makhoul et al.
Archives of disease in childhood, 98(7), 565-567 (2013-05-02)
Patricia Mabel Pintos et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 65(1), 39-51 (2013-06-12)
Propranolol (P) treatment exerts a preventive effect against the detrimental consequences to bone status in mildly chronically food-restricted growing rats (NGR) by an increment in cortical bone and by improving its spatial distribution. To study the effect of beta-blocker on

商品

This article highlights the impact that sample matrix effects can have on LC/MS response and discusses two novel approaches to reduce it.

Learn about Supel™ BioSPME C18 high-throughput devices to determine plasma protein binding and decrease the sample preparation time to less than an hour.

Comparative analysis of Supel™ BioSPME 96-Pin device with a rapid equilibrium dialysis technique for accuracy of measured values, sample cleanliness, and workflow time in drug protein binding.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门